Literature DB >> 18500238

SERCA2a gene therapy for heart failure: ready for primetime?

Muthu Periasamy1, Anuradha Kalyanasundaram.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18500238      PMCID： PMC4854184          DOI： 10.1038/mt.2008.89

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   12.910


× No keyword cloud information.
  21 in total

1.  Ca2+ handling and sarcoplasmic reticulum Ca2+ content in isolated failing and nonfailing human myocardium.

Authors:  B Pieske; L S Maier; D M Bers; G Hasenfuss
Journal:  Circ Res       Date:  1999-07-09       Impact factor: 17.367

2.  Enhanced myocardial contractility and increased Ca2+ transport function in transgenic hearts expressing the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+-ATPase.

Authors:  E Loukianov; Y Ji; I L Grupp; D L Kirkpatrick; D L Baker; T Loukianova; G Grupp; J Lytton; R A Walsh; M Periasamy
Journal:  Circ Res       Date:  1998-11-02       Impact factor: 17.367

3.  Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a.

Authors:  S E Harding; U Schmidt; T Matsui; Z B Kang; G W Dec; J K Gwathmey; A Rosenzweig; R J Hajjar
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

4.  Heart failure: a silver bullet to treat heart failure.

Authors:  R J Hajjar; R J Samulski
Journal:  Gene Ther       Date:  2006-07       Impact factor: 5.250

5.  Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats.

Authors:  Kazuo Niwano; Masashi Arai; Norimichi Koitabashi; Atai Watanabe; Yasuhiro Ikeda; Hiroyuki Miyoshi; Masahiko Kurabayashi
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

Review 6.  Targeted gene transfer in heart failure: implications for novel gene identification.

Authors:  Federica del Monte; Eddy Kizana; Adel Tabchy; Roger J Hajjar
Journal:  Curr Opin Mol Ther       Date:  2004-08

7.  New efficient catheter-based system for myocardial gene delivery.

Authors:  Ronen Beeri; J Luis Guerrero; Gregory Supple; Suzanne Sullivan; Robert A Levine; Roger J Hajjar
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

8.  Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium.

Authors:  M Arai; N R Alpert; D H MacLennan; P Barton; M Periasamy
Journal:  Circ Res       Date:  1993-02       Impact factor: 17.367

Review 9.  Gene therapy in the treatment of heart failure.

Authors:  Hung Ly; Yoshiaki Kawase; Ryuichi Yoneyama; Roger J Hajjar
Journal:  Physiology (Bethesda)       Date:  2007-04

10.  Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium.

Authors:  G Hasenfuss; H Reinecke; R Studer; M Meyer; B Pieske; J Holtz; C Holubarsch; H Posival; H Just; H Drexler
Journal:  Circ Res       Date:  1994-09       Impact factor: 17.367
View more
  7 in total

1.  Myostatin regulates tissue potency and cardiac calcium-handling proteins.

Authors:  Melissa F Jackson; Naisi Li; Buel D Rodgers
Journal:  Endocrinology       Date:  2014-02-11       Impact factor: 4.736

2.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.

Authors:  Mariell Jessup; Barry Greenberg; Donna Mancini; Thomas Cappola; Daniel F Pauly; Brian Jaski; Alex Yaroshinsky; Krisztina M Zsebo; Howard Dittrich; Roger J Hajjar
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

3.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

Authors:  Brian E Jaski; Mariell L Jessup; Donna M Mancini; Thomas P Cappola; Daniel F Pauly; Barry Greenberg; Kenneth Borow; Howard Dittrich; Krisztina M Zsebo; Roger J Hajjar
Journal:  J Card Fail       Date:  2009-04       Impact factor: 5.712

4.  HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization.

Authors:  Vidhya Sivakumaran; Brian A Stanley; Carlo G Tocchetti; Jeff D Ballin; Viviane Caceres; Lufang Zhou; Gizem Keceli; Peter P Rainer; Dong I Lee; Sabine Huke; Mark T Ziolo; Evangelia G Kranias; John P Toscano; Gerald M Wilson; Brian O'Rourke; David A Kass; James E Mahaney; Nazareno Paolocci
Journal:  Antioxid Redox Signal       Date:  2013-10-10       Impact factor: 8.401

5.  The cardiac translational landscape reveals that micropeptides are new players involved in cardiomyocyte hypertrophy.

Authors:  Youchen Yan; Rong Tang; Bin Li; Liangping Cheng; Shangmei Ye; Tiqun Yang; Yan-Chuang Han; Chen Liu; Yugang Dong; Liang-Hu Qu; Kathy O Lui; Jian-Hua Yang; Zhan-Peng Huang
Journal:  Mol Ther       Date:  2021-03-05       Impact factor: 12.910

6.  Determination of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies in Patients With Heart Failure in the Cardiovascular Foundation of Colombia (ANVIAS): Study Protocol.

Authors:  Melvin Y Rincon; Carlos E Prada; Marcos Lopez; Victor Castillo; Luis Eduardo Echeverria; Norma Serrano
Journal:  JMIR Res Protoc       Date:  2016-06-09

7.  Intracoronary Sarcoplasmic Reticulum Calcium-ATPase Gene Therapy in Advanced Heart Failure Patients with reduced Ejection Fraction: A Prospective Cohort Study.

Authors:  Jianfeng Zhang; Guojin Hu; Shengyong Yang
Journal:  Clinics (Sao Paulo)       Date:  2020-03-13       Impact factor: 2.365
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.